COMP <GO>
SMR vs TMO // OPERATING MARGIN
NuScale Power Corporation (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: SMR 2
— TMO 12
▲ OPERATING MARGIN LEADER: TMO
LAST: $5.62 (-5.07%) • MKT CAP: $2.54B
operating-margins
-60.00%
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
operating-margins
17.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SMR VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SMR | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 36.30% | 41.00% | -4.70 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 9.30% | -44.30 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 30.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -18.00% | 2.40% | -20.40 | TMO | /fcf-yield <GO> |
| Operating Margin ACTIVE | -60.00% | 17.40% | -77.40 | TMO | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 15.10% | -75.10 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | -15.00% | 3.90% | -18.90 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.62 | 4.50 | -0.88 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 8/9 | -5.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 6.70% | +0.70 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.2 | 59.1 | -23.97 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.14 | 0.94 | +0.20 | SMR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.0x | 36.3x | -17.30 | SMR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.54B | $262.22B | -$259.67B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SMR REV | TMO REV | SMR GROSS % | TMO GROSS % | SMR FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $31.5M | $44.56B | 36.3% | 44.0% | -$460.1M | $6.29B |
| FY 2024 | $37.0M | $42.88B | 86.7% | 44.0% | -$108.7M | $7.27B |
| FY 2023 | $22.8M | $42.86B | 44.0% | 44.0% | -$184.3M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SMR // BETA 1.14
TMO // BETA 0.94